Could a transplant drug help fight glioblastoma?
NCT ID NCT04477200
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether adding the drug mycophenolate mofetil (MMF) to standard radiation therapy is safe for people with glioblastoma, an aggressive brain cancer. About 68 participants with newly diagnosed or recurrent glioblastoma will receive different doses of MMF along with radiation. The main goals are to find the highest safe dose and to measure how much drug reaches the tumor.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mycophenolate mofetil (MMF), an immunosuppressant drug, combined with radiation therapy
What this could lead to
If successful, this could point toward a new way to treat glioblastoma by making radiation more effective.
What could go wrong
This is a very early (phase 0/1) trial with only 68 people, so it is mainly about safety and dosing. It may not lead to a proven treatment, and side effects from the drug or radiation could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States